A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC-4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs RG 7882 (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Genentech
- 27 Oct 2017 Planned End Date changed from 30 Dec 2017 to 14 Apr 2018.
- 27 Oct 2017 Planned primary completion date changed from 30 Dec 2017 to 14 Apr 2018.
- 05 Jun 2017 Planned number of patients changed from 75 to 100.